RxDoctor Payments Data

Kathy Clewell, MD

Internal Medicine · Poway, CANPI 1326100835

Payments from drug & device makers

$13,105in general payments, 2019–2025

Across 355 payments — averaging $36.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$5K
  • Biohaven Pharmaceutical Holding Company Ltd.$2K
  • GSK$866
  • Amgen$588
  • Novartis$543
  • AstraZeneca$470
  • plus $4K from 37 others

What the payments were for

  • Consulting fees$5,25040%
  • Travel & lodging$7266%
  • Food & beverage$7,12954%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$13,105 in reported general payments places this provider in the 90th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$441,071
Medicare patients
297
Services billed
9,441

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban48$75,242
FarxigaDapagliflozin Propanediol43$50,947
Repatha SureclickEvolocumab43$49,016
MounjaroTirzepatide27$40,442
MyrbetriqMirabegron35$35,247
TrulicityDulaglutide24$34,351
KerendiaFinerenone21$23,537
JanuviaSitagliptin Phosphate14$22,290
EntrestoSacubitril/Valsartan19$16,127
OzempicSemaglutide15$15,693
XareltoRivaroxaban14$14,419
Trelegy ElliptaFluticasone/Umeclidin/Vilanter11$7,116
TrulancePlecanatide11$6,037
Valsartan177$4,658
Wixela InhubFluticasone Propion/Salmeterol16$3,073

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Paxlovid$298$78,10185 claims
Lilly USA, LLCMounjaro, Trulicity$5,119$74,79251 claims
AstraZenecaFarxiga$470$50,94743 claims
Astellas Pharma US IncMyrbetriq$18$35,24735 claims
BayerKerendia$163$23,53721 claims
MerckJanuvia$96$22,29014 claims
NovartisEntresto$543$16,12719 claims
Novo NordiskOzempic$414$15,69315 claims
GSKTrelegy Ellipta$866$7,11611 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCTrulance$30$6,03711 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 13,581 internal medicine providers in California.

Other internal medicine in Poway

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →